Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial.

Lancet Microbe · 2025 · PMC12173475 · PMID 40194532

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

did not reach statistical significancep=0·076so close (0.05 < p ≤ 0.1)

At week 4, LACTIN-V participants had a median fold change in IL-1α from the visit before metronidazole of 0·415 (IQR 0·221–1·532) compared with 1·048 (0·539–4·334) in the placebo, although this difference did not reach statistical significance (p=0·076; figure 4B , appendix p 11).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.